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Available online 27 March 2008Substance abuse and addiction are the most costly of all the neuropsychiatric disorders. In
the last decades, much progress has been achieved in understanding the effects of the drugs
of abuse in the brain. However, efficient treatments that prevent relapse have not been
developed. Drug addiction is now considered a brain disease, because the abuse of drugs
affects several brain functions. Neurological impairments observed in drug addicts may
reflect drug-induced neuronal dysfunction and neurotoxicity. The drugs of abuse directly or
indirectly affect neurotransmitter systems, particularly dopaminergic and glutamatergic
neurons. This review explores the literature reporting cellular and molecular alterations
reflecting the cytotoxicity induced by amphetamines, cocaine and opiates in neuronal
systems. The neurotoxic effects of drugs of abuse are often associated with oxidative stress,
mitochondrial dysfunction, apoptosis and inhibition of neurogenesis, among other
mechanisms. Understanding the mechanisms that underlie brain dysfunction observed in
drug-addicted individuals may contribute to improve the treatment of drug addiction,
which may have social and economic consequences.
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Addictions are the most expensive of the neuropsychiatric
disorders (Uhl and Grow, 2004) mainly due to the costs of
health care, productivity loss and crime (United Nations Office
on Drugs and Crime, 2007; Office of National Drug Control
Policy, 2004).
Worldwide, the annual prevalence of illicit drug abuse is
about 4.8% of the world population, but some countries
present much higher prevalences (Table 1). In Europe, opiates
are the most problematic drugs, being responsible for 60% of
the treatment demands (European Monitoring Centre for
Drugs and Drug Addiction, 2007).
Addiction is a chronic relapsing disease (Leshner, 1997),
often accompanied by several neurological impairments such
as deficits in cognition, motivation, insight and attention,
behavioural disinhibition, emotional instability, depression,
anhedonia, impulsiveness, aggressiveness and movement
disorders (Majewska, 1996; Pau et al., 2002).
The main characteristic of drug addiction is the compulsive
drug use despite serious negative consequences. Drugs become
more important than other goals and all activities are directed
towards obtaining and consuming the drugs (Hyman et al.,
2006). The use of drugs leads to the desired psychoactive effect,
but also leads to toxic side-effects and to drug dependence,
followed by short-term and long-term health and social
problems due to a reduction in life-sustaining activities. In
this review, we describe the neurological impairments
observed in amphetamine, cocaine and opiate abusers, corre-
lating these impairments with the cellular and molecular
effects of the drugs of abuse in the brain.
1.1. Neurological impairments
As previously noticed, drug abusers present several neurologi-
cal impairments. Cocaine abusers may suffer from seizures
(Koppel et al., 1996), cerebral ischaemia, cerebral hemorrhages,
infarction, optic neuropathy, cerebral atrophy, cognitive
impairment, and mood and movement disorders (Majewska,Table 1 – Annual prevalence of drug abuse in Europe,
USA and worldwide
Annual prevalence (% of population)
Europe USA World
Cannabis 5.6 12.6 3.8
Amphetamines 0.5 1.8 0.6
Opiates 0.7 0.6 0.4
Cocaine 0.75 2.8 0.3
Ecstasy 0.6 1.0 0.2
Source:WorldDrugReport, 2007 (http://www.unodc.org/pdf/research/
wdr07/WDR_2007.pdf).1996). Brain lesions and cerebral atrophyaremainly observed in
the prefrontal cortex and basal ganglia of human cocaine
abusers (Bartzokis et al., 1996; Langendorf et al., 1996). Some
authors defend that vasoconstriction and consequent hypoxia
may be the primary cause of brain dysfunction induced by
cocaine (Olsen, 1995). Importantly, prenatal brain toxicity con-
stitutes a serious negative effect of cocaine (Nassogne et al.,
1998).
Heroin neuropathology often involves hypoxic-ischaemic
changes with cerebral edema, ischaemic neuronal damage and
neuronal loss. These effects may be due to prolonged heroin-
induced respiratory depression and to infections (Buttner et al.,
2000).Heroinabuserspresentcerebralatrophy (WolfandMikhael,
1979), demyelination (Lyoo et al., 2004), cerebral blood perfusion
abnormalities (Rose et al., 1996), and decreased neuronal
density in the globus pallidus (Pearson et al., 1976). Neuro-
pathological changes in heroin abusersmay also be caused by
adulterants.
Comparative studies between chronic amphetamine and
opiate drug users showed that these individuals displayed
pronounced neuropsychological impairment in the domains
of executive andmemory functions. Upon several years of drug
abstinence these impairments persisted, suggesting neuro-
pathology in frontal and temporal cortices (Ersche et al., 2006).
Post-mortem studies indicate that neuropathology in amphe-
tamine users is more severe and more specific, when
compared to opiate users. Brains of opiate users presented
non-specific ventricular and cortical volume loss, whereas in
the brains of psychostimulant users the prefrontal andmedial
temporal lobe areas were particularly affected (Ersche et al.,
2006). Chronic drug abuse seems to be associated with altered
monoamine activity, whichmay be responsible by some of the
behavioural deficits observed in drug addicts (Rogers and
Robbins, 2001).2. Drugs of abuse and the brain
Drugs of abuse interact with the brain, affecting brain systems
that respond to physiological stimuli such as food, water and
social interaction, which are critical to survival. Imaging
studies, using positron emission tomography (PET) and func-
tionalmagnetic resonance imaging (fMRI), have implicated the
involvement of different brain circuits in drug addiction
(reviewed by Volkow et al., 2003). The interaction of the drugs
with these circuits may be different in the different phases of
drug addiction: intoxication, withdrawal, bingeing and craving
(reviewed by Goldstein and Volkow, 2002).
The main brain circuits and structures implicated in the
effects of the drugs are the ones that mediate reward (nucleus
accumbens (NAc) and ventral pallidum), memory and learning
(amygdala and hippocampus), motivation/drive (orbitofrontal
cortex (OFC) and subcallosal cortex) and control (prefrontal
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In drug-addicted individuals, a loss of inhibitory control from
the prefrontal cortex impairs the regulation of the activity of
the other circuits, perpetuating the cycle of addiction.
Relapse to drug use is often precipitated by drug-associated
cues, which activate cortical regions (such as the anterior
cingulate cortex and the orbitofrontal cortex) and the insula,
as determined by imaging studies (PET and fMRI) (Volkow
et al., 2003). The function of the insula, which is involved in
conscious emotional feelings, seems to be essential tomediate
relapse (Naqvi et al., 2007).
The brain areas involved in the circuits affected by drug
addiction are innervated by dopaminergic and glutamatergic
projections, and modifications in these projections mediate
many of the adaptations involved in drug addiction. Two
dopaminergic brain pathways (the reward pathway and the
nigrostriatal pathway)mediatemanyof the effects of thedrugs
of abuse. The reward pathway is acutely activated by all the
drugs of abuse, and mediates the reinforcing effects of these
drugs. This pathway consists in theprojectionof dopaminergic
neurons in the ventral tegmental area (VTA) to several
structures involved in emotions, thoughts, memories and
planning and executing behaviours. One of these structures,
implicated in the addictive effects of the drugs, is the NAc, in
the ventral striatum. This structure is involved in reward and
addiction, but also inmotivation and learning (Di Chiara et al.,
1999). Another brain structure receiving projections from VTA
neurons is the prefrontal cortex, which coordinates executive
functions. The nigrostriatal pathway is involved in motor and
motivational aspects of behaviour (Gerfen, 1984) and is
composed by dopaminergic neurons that project from the
substantia nigra pars compacta to the caudate-putamen.
Several drugs of abuse increase extraneuronal dopamine in
dopaminergic nerve terminals in the striatum (Pereira et al.,
2004, 2006a). Dopamine and excitatory amino acids were
suggested to play an important role in the nigrostriatal
dopaminergic damage induced by methamphetamine
(Schmidt et al., 1985; Sonsalla et al., 1989). Interestingly, there
is a marked difference in specificity between methampheta-
mine andMDMA regarding the neurotransmitter systems and,
consequently, the brain areas affected by each of these
compounds. Whereas methamphetamine preferentially
affects dopaminergic brain areas, MDMA is more selective to
serotonergic brain areas (reviewed by Green et al., 2003).
2.1. Effects of metabolites and adulterants
Theeffectsofa givendrugofabuse, including its toxicity,maybe
affected by compounds resulting from its metabolism, particu-
larly when these compounds are able to cross the blood brain
barrier (BBB). Cocaine metabolism gives rise to active com-
pounds that cross theBBB,namelybenzoylecgonine,norcocaine
andcocaethylene.Cocaethylene results fromtransesterification
of cocaine and ethanol and is responsible by the synergistic
effects of cocaine and ethanol on the brain (Bunney et al., 2001).
Cocaine metabolism also originates inactive compounds, such
as ecgoninemethyl ester, ecgonine andmethyl ecgonine,which
were shown not to induce neurotoxicity in cortical neurons.
However, in the same conditions, cocaine and norcocaine
were neurotoxic (Nassogne et al., 1998). Since cocaine and nor-cocaine, in contrast to the non-toxic metabolites, are cationic
amphiphiles, it has been suggested that the neurotoxicity
induced by cocaine may require intracellular penetration of
cocaine and trapping in an acidic intracellular compartment
(Nassogne et al., 1998), since when positively charged it may
accumulate in negatively charged compartments, such as
mitochondria.
The metabolism of D-amphetamine produces the active
compounds norephedrine, hydroxyamphetamine and hydro-
xynorephedrine (Jenkins and Cone, 1998), but the extent of
D-amphetaminemetabolization ismuch lower,whencompared
with cocaine. In contrast, metabolism of the amphetamine
derivative ecstasy (or 3,4-methylenedioxymethamphetamine,
MDMA) seems to be important for its neurotoxicity. The cate-
chol metabolite N-methyl-α-methyldopamine that results from
O-demethylenation of MDMA and the catechol metabolites
resulting fromN-demethylation followed byO-demethylenation
of MDMA, such as α-methyldopamine and 6-hydroxy-α-methyl-
dopamine,were shown to beneurotoxic, andmaybe responsible
byMDMA toxicity in catecholaminergic PC12 cells. In these cells,
MDMA and its metabolites 3,4-methylenedioxyamphetamine
(MDA) and3-methoxy-α-methyldopaminewere showntobe less
toxic (Milhazes et al., 2006). In cortical neurons, MDMA and its
metabolites N-methyl-α-methyldopamine and α-methyldopa-
mine were also shown to be neurotoxic (Capela et al., 2006a).
Furthermore, thioether MDMA metabolites were demonstrated
to be stronger neurotoxins in comparison with their parent
catechols and MDMA, in cultures of rat cortical neurons (Capela
et al., 2007b).
Heroin metabolism occurs readily upon self-administra-
tion, by the deacetylation to the active metabolites 6-mono-
acetyl morphine (6-MAM) and morphine. The formation of 6-
MAM may occur spontaneously in aqueous media. Hence,
heroin may be considered as a pro-drug, because it does not
have intrinsic activity, but, due to its high lipophilicity it
facilitates the distribution of the active metabolites, 6-MAM
and morphine (Sawynok, 1986). Since morphine can induce
neurotoxicity (Hu et al., 2002; Mao et al., 2002; Lim et al., 2005),
it may contribute to the neurotoxic effects of heroin. However,
we showed that 6-MAM and morphine do not contribute to
street heroin neurotoxicity in cultured cortical neurons
(Cunha-Oliveira et al., 2007). In accordance, a recent study
suggests that heroin has a higher neurotoxic potential in
comparison with morphine (Tramullas et al., 2008).
Contaminants and adulterants may also be implicated in
the effects and toxicity of the drugs. We have previously
shown that street heroin with a purity of 27% was more toxic
to PC12 cells than 62% pure heroin (Oliveira et al., 2002).
Moreover, the latter form of heroin induced a large activation
of caspase-3 in rat cortical neurons, whereas ~100% pure
heroin hydrochloride only slightly activated this caspase
(Cunha-Oliveira et al., 2007).
Another factor affecting the effects of the drugs is poly-
abuse. Interactions betweenmolecules of different drugs, such
as cocaine and morphine (Garrido et al., 2007) may lead to
distinct effects when compared to the drugs alone.
In order to analyse the factors leading to the neurotoxicity
of the drugs of abuse, upon acute or chronic exposure, it is
important to understand the short-term and long-term
neurochemical effects of these drugs.
Fig. 1 – Direct effects of (A) amphetamine and (B) cocaine in
dopaminergic nerve terminals. Both drugs increase
extracellular dopamine accumulation by different
mechanisms. In a simplified manner, amphetamine inhibits
the storage of dopamine in synaptic vesicles, inducing an
increase in cytosolic dopamine concentration and reversal of
the DAT. Cocaine blocks the reuptake of dopamine by the
DAT. Formore detailed explanation see text. TYR— tyrosine,
TH— tyrosine hydroxylase,
L-DOPA— L-dihydroxyphenylalanine, AADC— Aminoacid
decarboxylase, Amph— amphetamine, Coc— cocaine,
DAT— dopamine transporter, MAO—monoamine oxidase,
VMAT— vesicular monoamine transporter,
DOPAC— dihydroxyphenylacetic acid.
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At the cellular level the drugs of abuse interfere with neuro-
transmitter systems by imitating (opiate drugs — endogenous
opioids, nicotine— acetylcholine), stimulating (cocaine, ampheta-
mines — dopamine, ecstasy — serotonin) or blocking (alcohol —
glutamate) the effects of the neurotransmitters (Hyman et al.,
2006).
The stimulant drugs amphetamine and cocaine directly
increase extraneuronal dopamine levels through different
mechanisms (Fig. 1). Amphetamine induces an increase in
extracellular monoamines, by interacting directly with mono-
aminergic cells (Fig. 1A). Although amphetamine has compar-
able effects in neurons containing serotonin, noradrenaline
and dopamine, the effects implicated in its reinforcing
properties are mainly mediated by dopamine (Fleckenstein
et al., 2007). Furthermore, dopamine synthesis is important for
methamphetamine toxicity in dopamine and serotonin sys-
tems (Schmidt et al., 1985).
Due to its structural similarity with dopamine, ampheta-
mine is a substrate for the dopamine transporter (DAT) (Sitte
et al., 1998). At low concentrations, amphetamine is trans-
ported by the DAT to the cytosol and increases the intracel-
lular binding sites of the DAT for dopamine, resulting in the
exchange of extracellular amphetamine by intracellular
dopamine, and leading to an increase in extracellular dopa-
mine (Jones et al., 1999). When present at higher extracellular
concentrations, amphetaminemay diffuse into the cell, due to
its lipophilicity (Sulzer et al., 1995; Kahlig et al., 2005).
Intracellular amphetamine also induces reverse transport by
the DAT because it contributes to increase the intracellular
dopamine concentration. Methamphetamine interferes with
the vesicular monoamine transporter 2 (VMAT-2) function,
rapidly redistributingVMAT-2 toanon-vesicular location (Riddle
et al., 2002), impairing the active transport of the monoamines
into synaptic vesicles, where they are stored. In addition,
amphetamine may enter in the vesicles by diffusion, due to its
weak base properties (Sulzer et al., 2005, for review). Since
amphetamine is a weak base, at acidic pH it accepts protons
leading to alkalinization inside the vesicles. A low pH inside the
vesicles is essential to maintain the proton gradient used by
VMAT-2 for active transport of monoamines into the vesicles.
Therefore, amphetamine induces the release of vesicular
dopamine to the cytosol and impairs the storage of dopamine
in the vesicles. Cytosolic dopamine is then released to the
extracellular space via reverse transport by the DAT. For more
detailed explanation the reader is referred to the excellent
review of Sulzer et al. (2005). The weak base effect explains
mitochondrial dysfunction induced by amphetamine in the
absence of dopamine, due to disruption of mitochondrial
potential (Cunha-Oliveira et al., 2006a), which may lead to a
decrease in intracellular ATP (Oliveira et al., 2002).
Amphetamine also interferes with dopamine synthesis. At
low concentrations, amphetamine promotes dopamine
synthesis (Kuczenski, 1975), whereas at higher concentrations
or upon prolonged exposure, it leads to tyrosine hydroxylase
(TH) inhibition (Ellison et al., 1978) or decreased TH protein
levels (Bowyer et al., 1998). Amphetamine also impairs
dopamine metabolism by inhibiting monoamine oxidase
(MAO) (Ramsay and Hunter, 2002).Amphetamine derivatives have common and distinct
effects when compared with amphetamine. While no major
differences are observed between amphetamine andmetham-
phetamine effects (Sulzer et al., 2005), despite a subtly greater
dopamine release induced by amphetamine in the prefrontal
cortex (Shoblock et al., 2003), MDMA has an enhanced potency
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when compared to amphetamine and methamphetamine
(Rothman and Baumann, 2003). MDMA is also an agonist of
5-HT2A receptors (Nash et al., 1994), and MDMA neurotoxicity
is often associated with depletion of serotonergic terminal
markers (reviewed by Green et al., 2003). However, whereas
MDMA is a serotonin neurotoxin in non-human primates and
rats, it is a dopaminergic neurotoxin in themouse (Logan et al.,
1988). Differences in MDMA effects among animal species
were previously reviewed by Green et al. (2003).
Cocaine inhibits the DAT (Brown et al., 2001), preventing
the reuptake of dopamine into the nerve terminal (Fig. 1B). The
inhibition of the DAT results in increased levels of dopamine
in the synaptic cleft. Cocaine also inhibits the monoamine
transporters noradrenaline transporter (NET) and serotonin
transporter (SERT) (Gatley et al., 1998). However, as it happens
with amphetamine, reinforcing effects of cocaine are largely
dependent on its effect in dopaminergic neurotransmission
(Ritz et al., 1987).
Cocaine also interacts with the VMAT-2 (Fig. 1B), favoring
the storage of catecholamines inside synaptic vesicles (Brown
et al., 2001). It was suggested that cocaine-induced inhibition
of the DAT and increased vesicular sequestration of dopa-
mine, causes a shift in the ratio of cytoplasmic to vesicular
dopamine, increasing the amount of neurotransmitter pack-
aged in each vesicle before its release. This effect on the
VMAT-2 would contribute to a further increase in synaptic
dopamine, upon a depolarizing stimulus (Brown et al., 2001).
Interestingly, cocaine metabolite cocaethylene is a more
selective indirect dopamine agonist than cocaine, with
relatively weak potency at the SERT (Jatlow et al., 1996).
In contrast with the stimulant drugs, opiates induce an
increase in dopamine in the NAc by an indirect mechanism.
The major targets of opiates are the opioid receptors, which
mediate the endogenous effects of the opioid neuropeptides.
Due to structural similarities with the opioid peptides, opiate
drugs of abuse bind to μ-opioid receptors present in gamma
aminobutyric acid (GABA)-releasing interneurons in the VTA,
inhibiting the release of GABA, an inhibitory neurotransmitter
that acts on dopaminergic neurons to inhibit dopamine
release. Thus, the action of the opiate drugs in the GABAergic
interneurons results in an increase in dopamine release by the
dopaminergic neurons of the VTA (Nestler, 2004b), which has
been associated with reward mechanisms.
2.3. Long-term neurochemical effects
Chronic exposure of neurons to drugs of abuse results in long-
lasting alterations in neuronal physiology, leading to the
development of drug addiction. For example, in chronic drug
abusers, withdrawal induces a marked decrease in dopamine
function in the brain (Volkow et al., 2004).
Adaptations to the drugs are in the basis for the develop-
ment of sensitization or tolerance, in which the response to
the same dose of a drug is increased or decreased, respec-
tively. These processes are responsible for the withdrawal
symptoms and increased motivation to drug abuse (Nestler,
2004a). These adaptations may be related to long-lasting
changes in gene expression, as observed in chronic drug
users, and some of these changes may be correlated with thedevelopment of the compulsive behaviour associated with
drug addiction (Rhodes and Crabbe, 2005, for review).
Opiates have the most evident addictive effects, involving
tolerance, withdrawal and a high rate of relapse. These effects
may be explained by activation of intracellular signaling
pathways that regulate gene expression, upon binding of
opioids to their receptors.
One of the best characterized neuroadaptations induced by
opioid drugs is the upregulation of the cAMP pathway that
occurs in neurons from the locus coeruleus (reviewed by
Nestler, 2004b) and NAc (Chieng and Williams, 1998). The
molecular mechanisms involved in the upregulation of cAMP
pathway seem to be partially mediated by the transcription
factor CREB. Chronic opiate exposure induces CREB expression
and activity, which is thought to mediate the expression of
some of the components of the cAMP pathway. Cocaine and
amphetamine also induce CREB activation due to an increase
in the stimulation of dopamine (D1) receptors (Hyman et al.,
2006, for review). CREB has many target genes, such as c-Fos,
corticotropin-releasing factor (CRF), TH, brain derived neuro-
trophic factor (BDNF), adenylyl cyclase (isoform VIIII), enke-
phalins anddynorphin (Carlezon et al., 2005). Theupregulation
of dynorphin seems to mediate the decrease in the rewarding
properties of the drugs, mediated by CREB (Cole et al., 1995).
Dynorphin acts on k-opioid receptors present on VTA neurons
to decrease dopamine release and represents a negative-
feedback loop. Upregulation of cAMP pathway by the opiates
leads to decreased dopamine release in the VTA when opiates
are present. When opiates are no longer present, the decrease
in dopamine releasemediated by dynorphinmay contribute to
anhedonia and dysphoria that characterize the early phases of
opiate withdrawal (Hyman et al., 2006, for review).
Changes in gene expression induced by chronic drug
exposure may also underlie changes in the cellular responses
to cytotoxic stimuli. In accordance, we observed that chronic
exposure of PC12 cells to cocaine, amphetamine (Cunha-
Oliveira et al., 2006c) and street heroin (Cunha-Oliveira et al.,
2006b) involves adaptations to oxidative stress.
2.3.1. Glutamate and neuroplasticity — implications for the
toxicity of drugs of abuse
Many evidences suggest the involvement of glutamatergic
neurotransmission in the mechanisms of drug dependence
involving the dopaminergic reward circuit in the brain
(Tzschentke and Schmidt, 2003). On the other hand, an
increase in extracellular glutamate has been associated with
excitotoxic processes, due to increased activation of NMDA
receptors and subsequent increase in intracellular Ca2+
concentration (for review, Rego and Oliveira, 2003).
Cocaine (You et al., 2007; Williams and Steketee, 2004;
Kalivas and Duffy, 1998; Reid et al., 1997) and amphetamine
(Anderzhanova et al., 2002; Reid et al., 1997; Abekawa et al.,
1994; Wolf and Xue, 1999) increase extracellular glutamate
concentrations in brain areas such as the VTA, NAc, prefrontal
cortex or striatum.
Moreover, amphetamine toxicity and behavioural effects
were previously shown to be attenuated by the NMDA re-
ceptor antagonist dizocilpine maleate (MK801) (Derlet et al.,
1990), suggesting that amphetamine enhances the activity of
NMDA receptors (Sonsalla, 1995). Furthermore, plasticity of
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brain adaptations induced by cocaine, and contributes to the
development of addictive behaviours (Schilstrom et al., 2006;
Wolf, 1998). Changes in the expression of NMDA receptor
subunits were observed in the brains of cocaine-exposed rats
(Huber et al., 2001; Schilstrom et al., 2006;Yamaguchi et al.,
2002; Scheggi et al., 2002). In VTA neurons, cocaine induced an
increase in NR1 and NR2B subunit expression and their
redistribution to synaptic membranes (Schilstrom et al.,
2006). NR2B expression was also shown to be increased
in the NAc and in the hippocampus of cocaine-exposed
rats. This effect was prevented in rats exposed to cocaine
and MK-801 (Scheggi et al., 2002). Cocaine-induced changes
in the expression of NMDA receptor subunits may be mediated
by extracellular dopamine, via stimulation of dopamine recep-
tors (Schilstrom et al., 2006). Interactions between NR2B
subunits of the NMDA receptor and the D2 dopamine recep-
tor were observed in the neostriatum of cocaine-exposed rats
(Liu et al., 2006) and may contribute to the stimulant effect of
cocaine.
Glutamatergic neurotransmission involving the NMDA
receptor contributes to opiate dependence in humans (Bisaga
etal., 2001). Ionotropic glutamate receptors in theVTAmodulate
opiate reinforcement (Xi and Stein, 2002). Moreover, NMDA
receptor antagonists inhibit the development of physical
dependence and tolerance (Trujillo, 2000). The NMDA receptor
antagonists memantine (Ribeiro Do Couto et al., 2004) and MK-
801 (Tzschentke and Schmidt, 1995) are capable of preventing
the acquisition of morphine-induced conditioned place-pre-
ference, suggesting that theglutamatergic systemcanmodulate
opiate reward.Moreover, theNMDAreceptor antagonistMK-801
was shown to specifically block morphine-induced tolerance
and neuronal apoptosis in the spinal cord (Mao et al., 2002).
Morphine dependence reduces the affinity of glycine for
NMDA receptors in the NAc (Siggins et al., 2003; Martin et al.,
2004). Moreover, morphine-dependent rats show decreased
NR1 and NR2A subunit expression in the frontal cortex and
hippocampus and increased levels of NR1 and NR2A in the
NAc, whereas NR2B is not affected (Murray et al., 2007). These
data suggest that NR2A-containing NMDA receptors in the
NAc probably contribute to the development of opiate
dependence. Another study also suggested that chronic
morphine induces an increase in NR2A subunit function in
the NAc, and a decrease in the function of the NMDA receptor
subunits NR2B and 2C, which could result in altered excit-
ability and integrative properties (Martin et al., 2004).
However, other authors showed that chronic morphine
significantly increased the protein levels of NR1 and NR2B
subunits in theNAc (Bajo et al., 2006). It was recently suggested
that NR2B subunit-containing NMDA receptors may be
involved in the rewarding effect of morphine (Kato et al.,
2007; Ma et al., 2007). NR2B-containing NMDA receptors in the
NAc and the dorsal hippocampus were proposed to play a
significant role in mediating the reinstatement of rewarding
responses tomorphine (Ma et al., 2007). This effect seems to be
specific for morphine because NR2B containing NMDA recep-
tors are more involved in morphine reward rather than in
natural rewards (Ma et al., 2006). Nevertheless, the acute
exposure to opiates may have different effects on NMDA
receptors when compared to the chronic exposure.Changes in the composition of NMDA receptors may
increase the susceptibility of cells to drug toxicity. We have
previously observed that NR1/NR2B transfected HEK293 cells
were more susceptible to acute street heroin toxicity when
compared to NR1/NR2A and NR1 transfected cells. Street
heroin toxicity was abolished by pre-incubation with MK-801
in NR1/NR2B expressing cells, suggesting the involvement of
these NMDA receptor subunits in street heroin toxicity
(Domingues et al., 2006).
2.4. Intracellular mechanisms of neurotoxicity induced by
amphetamines, cocaine or heroin
Since addiction may be considered a brain disease (Leshner,
1997), neurotoxicity may underlie some of the effects of the
drugs. The Interagency Committee on Neurotoxicology defined
neurotoxicity as a broad concept, including any adverse effect
on the structure or function of the central and/or peripheral
nervous system by a biological, chemical or physical agent. In
this definition, neurotoxic effects may be permanent or re-
versible and result fromdirect or indirect actionson thenervous
system (Erinoff, 1995).
Thebrain isparticularly sensitive to toxicity, because it isone
of themostmetabolically active tissues. A continuous supply of
glucose is essential for the energy-consuming neuronal func-
tions such as axonal transport or synaptic transmission.
Although new neurons may be formed by neurogenesis in the
adult brain (Gage, 2002), the existing neurons do not divide and
thus dysfunction or death of these cells may result in
irreversible damage. Furthermore, the brain is highly sensitive
to oxidative stress due to its high content in polyunsaturated
fatty acids, low levels of antioxidants, the presence of transition
metals and high levels of oxygen consumption.
As previously discussed, drugs of abuse compromise
important brain functions, what may in part result from
their neurotoxicity. However, the neurotoxic effects of the
drugs of abuse may be enhanced by environmental factors,
such as elevated temperature and loud noise (Gesi et al., 2004;
Capela et al., 2006b). In contrast, stress manipulations (e.g.
restraint stress) protect mice against dopaminergic toxicity
induced by repeated MDMA treatment (Johnson et al., 2004).
Thus, environmental factors may determine the extent of the
neurotoxic damage produced by the drugs of abuse.
Neurotoxicity induced by the drugs of abuse may be
evaluated by several parameters. Herein we report the
intracellular mechanisms of neurotoxicity of amphetamine,
amphetamine derivatives, cocaine and heroin, associated
with mitochondrial dysfunction, and oxidative stress, which
may lead to cell death by apoptosis. However, other functional
and morphological hallmarks of neurotoxicity induced by
psychostimulant drugs of abuse have been described, such as
changes in protein degradation (involving inhibition of the
proteosome and autophagy) and resulting in the appearance
of neuronal inclusions (Iacovelli et al., 2006, for review).
2.4.1. Oxidative stress caused by dopamine and drugs of abuse
2.4.1.1. Dopamine and oxidative stress. As described in the
previous sections, virtually all of the drugs of abuse induce an
increase in extracellular monoamines in specific regions of
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mine is mainly observed in monoaminergic brain areas,
particularly in dopaminergic nerve terminals in the striatum
(Gibb and Kogan, 1979). Moreover, dopamine has been shown
to be neurotoxic in vitro (Graham et al., 1978; McLaughlin et al.,
1998) and in vivo (Hastings et al., 1996). Dopamine is easily
oxidized, by enzymatic and non-enzymatic mechanisms, and
may induce oxidative stress in dopaminergic and neighboring
cells. This may contribute to the neurotoxicity of the drugs of
abuse.
Synaptic activity of dopamine is mainly regulated by two
mechanisms: reuptake, responsible for 70–80% of dopamine
recycling, and/or inactivation (metabolism) (Amara and
Kuhar, 1993). Dopamine may be metabolized intracellularly
by MAO, a mitochondrial enzyme, present in the cytoplasmic
side of the outer membrane. MAO catalyses the deamination
of dopamine producing 3,4-dihydroxyphenylacetic acid
(DOPAC) and hydrogen peroxide (H2O2). Dopamine auto-
oxidation produces the superoxide anion (O2U−) and H2O2,
which may react with transition metal ions, via the Haber–
Weiss/Fenton reactions, originating the highly toxic hydroxyl
radical (UOH). Furthermore, O2U− reacts with nitric oxide,
forming the highly toxic peroxinitrite (Cadet and Brannock,
1998). Thus, dopamine is both a neurotransmitter and a
neurotoxin, and changes in dopamine metabolism may
induce oxidative stress and cell death in dopaminergic or
surrounding cells (Jones et al., 2000) if the antioxidant systems
are not able to deal with the increase in the levels of ROS. An
increase in ROS levels may lead to cell death due to the
oxidation of important cellular macromolecules such as
amino acids, phospholipids and nucleic acids (Cadet and
Brannock, 1998).
Themainantioxidant enzymes involved inH2O2 inactivation
are glutathione peroxidase (GPx) and catalase (present in the
peroxisomes). Superoxide dismutase (SOD), another antioxi-
dant enzyme, may contribute to increase H2O2 levels by de-
toxification of O2U−. The levels and the activity of these enzymes
are regulated by the cells and are important tomaintain cellular
homeostasis. Therefore, the effects of chronic exposure to
oxidants contrast with the effects of acute exposure. For ex-
ample, acute exposure to H2O2 induces apoptotic cell death
(Benedi et al., 2004; Jang and Surh, 2004), whereas chronic
exposure to low concentrations of H2O2 induces cellular resis-
tance to the acute toxicity of this compound (Wiese et al., 1995;
Davies, 1999). Acute exposure to H2O2 may then be used as a
model of cytotoxicity whereas chronic treatment with a low
concentrationofH2O2maybeamodel of cell adaptation (Jackson
et al., 1994).
Evidences of oxidative stress induced by amphetamine,
amphetamine derivatives, cocaine and opiates are discussed
in the following sections.
2.4.1.2. Amphetamines and oxidative stress. Exposure to
amphetamine or amphetamine derivatives has been shown
to induce oxidative stress in the nervous system (Table 2), and
this was the subject of previous reviews (Yamamoto and
Bankson, 2005;Cadet et al., 2007). Methamphetamine and
D-amphetamine have been shown to increase ROS levels upon
in vitro (Wu et al., 2007; Pubill et al., 2005) or in vivo (Frey et al.,
2006a; Jimenez et al., 2004) exposure and the toxic effects ofthese drugs may be prevented by antioxidants. Moreover, in
methamphetamine human abusers the activity of antioxidant
enzymes was affected in several regions of the brain (Mirecki
et al., 2004). In animal models, methamphetamine (Acikgoz
et al., 2000) and D-amphetamine (Frey et al., 2006b; Carvalho
et al., 2001) also affected the activity of antioxidant enzymes.
In addition, evidences of oxidative damage have been reported
in the brains of metamphetamine human abusers (Fitzmaur-
ice et al., 2006) andmethamphetamine (Acikgoz et al., 2000) or
D-amphetamine (Frey et al., 2006a) exposed animals. In
catecholaminergic cell cultures, we have previously shown
that chronic exposure to D-amphetamine induces a partial
protection against H2O2-induced toxicity, which was sug-
gested to be associated with adaptation to oxidative stress
(Cunha-Oliveira et al., 2006c).
MDMA-induced oxidative stress was also reported. Meta-
bolization of MDMA to catechol or quinone compounds, which
are capable of forming free radicals, may be responsible for the
oxidative damage induced by MDMA (Green et al., 2003, for
review). Thioether MDMA metabolites may also induce
oxidative stress in neurons (Capela et al., 2007b). In addition,
since MDMA also induces dopamine release in rats (Amato
et al., 2007), dopamine metabolism may also explain MDMA-
induced oxidative stress.
Hydroxyl radical formation was reported in the hippocam-
pus and striatum of rats upon peripheral injection of MDMA
(Shankaran et al., 2001), and was dependent on SERT activity
(Shankaran et al., 1999). Furthermore, depletion of GSH upon
MDMA exposure was observed in vitro in rat cortical neurons
(Capela et al., 2007a) and in vivo in the mouse hippocampus,
along with a decrease in Cu/Zn SOD activity (Frenzilli et al.,
2007). In vivo exposure to MDMA was also reported to induce
an increase in lipoperoxides and protein carbonyls, accom-
panied bymitochondrial DNA deletions, in isolatedmitochon-
dria from adolescent rat brains (Alves et al., 2007). In addition,
lipoperoxides were detected by other authors in the brains of
rats exposed to MDMA (Sprague and Nichols, 1995; Colado
et al., 1997). Another evidence of MDMA induced-oxidative
stress is the fact that transgenic mice that overexpress Cu/Zn
SOD are resistant to MDMA toxicity (Jayanthi et al., 1999).
2.4.1.3. Cocaine and oxidative stress. The occurrence of
oxidative stress in neurons, upon exposure to cocaine has
beenmuch less studied, when compared to amphetamine and
amphetamine derivatives. Cocaine exposure has been
reported to increase H2O2 in the prefrontal cortex and in the
striatum of rats (Dietrich et al., 2005). Cocaine exposure was
also shown to induce a decrease in catalase activity (Macedo
et al., 2005), as well as an increase in SOD and GPx activities
(Dietrich et al., 2005) in the cortex and in the striatum of
animals. The levels of antioxidants such as GSH or reduced
vitamin E have been also shown to be decreased upon cocaine
exposure (Poon et al., 2007; Lipton et al., 2003). Furthermore,
cocaine exposure also results in oxidative injury in the brain,
as indicated by an increase in lipid peroxidation (Bashkatova
et al., 2006) and oxidation of proteins (Poon et al., 2007).
Adaptation to oxidative stress induced by cocainemay explain
the significant protection against H2O2 toxicity observed in
PC12 cells, upon chronic exposure to cocaine (Cunha-Oliveira
et al., 2006c).
Table 2 – Summary of recent studies showing evidences of oxidative stress induced by amphetamine or amphetamine
derivatives
Drug Biological model Mechanisms Dose/time of
exposure
Reference
Meth Human SH-SY5Y cell line ↓ΔΨm Acute: 0.7–1.68 mM;
24–72 h
(Wu et al., 2007)
↑ROS
Protected by vitamin E






Acute toxicity not prevented by H2O2 adaptation Chronic: 30 μM;
7–12 months
Meth Human caudate and
frontal cortex
↑4-HNE – (Fitzmaurice et al.,
2006)↑MDA
D-Amph In vivo: Wistar rats Acute: ↑SOD prefrontal cortex for 1 mg/kg 1 mg/kg, 2 mg/kg,
or 4 mg/kg
(Frey et al., 2006b)
Prefrontal cortex, striatum,
hippocampus Chronic: ↑SOD hippocampus; ↓SOD striatum for 1
and 4 mg/kg
Acute: 1 day
↑Catalase prefrontal cortex and hippocampus for
4 mg/kg
Chronic: 7 days
↓Catalase hippocampus and striatum for 2mg/kg
Chronic exposure: ↑TBARS and ↑Superoxide in
prefrontal cortex and hippocampus
(Frey et al., 2006a)
D-Amph In vivo: rat brain ↑GST — hypothalamus Chronic (14 days)
20 mg/kg/day
Carvalho et al. (2001)
↑GPx — striatum, nucleus accumbens and medial
prefrontal cortex
↑GRed — hypothalamus
↑Catalase — medial prefrontal cortex
↓GRed — medial prefrontal cortex
Meth Striatal synaptosomes
(Wistar rat)
↑ROS Acute 2 h, 2 mM Pubill et al., (2005)
Protected by antioxidants
Meth Human caudate ↑SOD – Mirecki et al. (2004)
↑GSSG
Meth In vivo: Wistar rats ↑SOD Acute 10–15 mg/kg Acikgoz et al. (2000)
Prefrontal cortex ↑TBARS
Striatum
MDMA In vivo: Wistar rats brain
mitochondria
↑LPO 4×10 mg/kg Alves et al. (2007)
↑Protein carbonyls 2 weeks after
exposureMitochondrial DNA deletions
Protected by selegiline (MAOB inhibitor)
MDMA In vivo: C57BL/6J mice,
hippocampus
↓GSH 2.5 mg/kg, 5 days Frenzilli et al. (2007)
↓Cu/Zn SOD Evaluated after 1,5
or 14 days
MDMA Rat cortical neurons ↓GSH 0.4 mM, 48 h Capela et al. (2007a)
Attenuated by 5HT2A antagonist ketanserine
MDMA In vivo: rat striatum ↑2,3-DHBA (hydroxyl radical marker) 20 mg/kg (s.c.) Shankaran et al. (1999)
Abbreviations: ΔΨm—mitochondrial potential, D-Amph— D-amphetamine, 2,3 DHBA— 2,3-dihydroxybenzoic acid, GSH— reduced glutathione,
GST—glutathione-S-transferase,GPx—glutathioneperoxidase,GRed—glutathione reductase,HNE—hydroxynonenal,meth—methamphetamine,
LPO— lipoperoxides, MDA—malondialdehyde, NAC—N-acetyl cysteine, NOS—nitric oxide synthase, ROS— reactive oxygen species, SOD—
superoxide dismutase, TBARS — thiobarbituric acid reactive substances.
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oxidative stress induced by cocaine are summarized in Table 3.
2.4.1.4. Opiates and oxidative stress. Although there is
much less literature presenting evidences about opiate-
induced oxidative stress in the nervous system when
compared to the psychostimulants, there is recent evidence
that the effects of morphine and heroin exposures in the
brain and spinal tissues may involve oxidative stress. Heroin
was shown to induce a decrease in the activities of SOD,
catalase and GPx in the mouse brain (Qiusheng et al., 2005; Xu
et al., 2006). Moreover, morphine induced a decrease in GSH
levels in the rat (Guzman et al., 2006) and rabbit brains(Ozmen et al., 2007), and also a decrease in unsaturated fatty
acids in the rabbit nervous system (Ozmen et al., 2007).
Oxidative lesions were also observed in the brains of opiate-
exposed animals. Morphine exposure induced an increase in
lipid peroxidation (Ozmen et al., 2007) and heroin exposure
induced an increase in oxidative DNA damage, protein oxi-
dation and lipid peroxidation (Qiusheng et al., 2005; Xu et al.,
2006). Partial protection against H2O2 toxicity was observed in
PC12 cells chronically exposed to street heroin, indicating
some degree of adaptation to oxidative stress (Cunha-Oliveira
et al., 2006b).
The results of recent studies presenting evidences of
oxidative stress induced by opiates are summarized in Table 4.
Table 3 – Summary of recent studies showing evidences of oxidative stress induced by cocaine
Biological model Mechanisms Dose/time of exposure Reference
PC12 cells Chronic: partial protection against
H2O2-induced toxicity
Acute: 3 Mm; 4 days Cunha-Oliveira et al.
(2006c)
Acute toxicity not prevented by H2O2
adaptation
Chronic: 30 μM; 7–12 months
In vivo: prenatal exposure — rat
hippocampus and cortex
Nitric Oxide Repeated: 20 mg/kg/day Bashkatova et al. (2006)
TBARS 4 days
Human neuronal progenitor cells Protein carbonyl Acute: 1 μM; 30 min; analysed
after 6–96 h
Poon et al. (2007)
Protein HNE
↓GSH
In vivo: Swiss mice, striatum and
frontal cortex
Low dose: ↓catalase in striatum Low dose: 10–30 mg/kg Macedo et al. (2005)
High dose: ↓catalase activity in cortex
and striatum
High dose: 90 mg/kg
In vivo: rat — frontal cortex and
striatum
↑H2O2 20 mg/kg/day Dietrich et al. (2005)
Lipoperoxidation Acute — 1 day
↓Complex I activity Chronic — 10 days
↑SOD, ↑GPx
In vivo: prenatal exposure — rat
brain
↓GSH Single Lipton et al. (2003)
↓reduced Vit E
↑oxidized Vit E
Abbreviations: Vit E — vitamin E. For other abbreviations see legend of Table 2.
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Induction of neuronal cell death by apoptosis by some drugs of
abuse has been documented. Programmed cell death can
occur through several tightly regulated pathways. Thus,
identification of cell death pathways induced by the drugs of
abuse may lead to strategies to prevent cell damage induced
by these drugs.
One of the most characterized types of cell death is
apoptosis. Morphological hallmarks of apoptotic cells are cell
shrinkage, fragmentation into membrane-bound apoptotic
bodies, chromatin condensation and fragmentation. Two
main molecular pathways of apoptosis have been character-Table 4 – Summary of recent studies showing evidences of ox
Drug Biological model Mechanisms





Heroin PC12 cells Chronic: protection against H2O2
induced toxicity
Acute toxicity potentiated upon
H2O2 adaptation
Heroin In vivo: mouse brain ↓SOD
↓CAT
↓GPx
↑Oxidative damage to DNA, lipid
and proteins
Morphine In vivo: rat brain ↓GSH







Abbreviations: GSH — reduced glutathione; SOD — superoxide dismutase
glutathione; 8-OHdG — 8-hydroxy-2-deoxyguanosine; MDA — malondialized, one being activated by extrinsic signals, involving the
activation of death-receptors in the cell membrane, and
another activated by intrinsic stimuli and involving mito-
chondrial membrane permeabilization. These pathways may
involve the activation of cysteine aspartic proteases, named
caspases, which are activated by proteolysis, or may be
caspase independent (Kroemer and Martin, 2005).
2.4.2.1. Amphetamines and apoptosis. Exposure to amphe-
tamine or amphetamine derivatives has been shown to induce
apoptotic features in animals and in cell models (Table 5).
Previous reviews have addressed this subject (Cadet et al.,idative stress induced by opiates
Dose/time of exposure Reference
6 mg/kg intraspinal Ozmen et al. (2007)
- Acute: 128 μg/ml (215 μM); 4 days Cunha-Oliveira et al. (2006b)
Chronic: 10 μM; 7–12 months
i.p. Xu et al. (2006)
s
Single i.p. 3, 6 or 12 mg/kg Guzman et al. (2006)
i.p. Qiusheng et al. (2005)
; CAT — catalase; GPx — glutathione peroxidase; GSSG — oxidized
dehyde, i.p. — intraperitoneal.
Table 5 – Summary of recent studies that analyse neuronal apoptosis induced by amphetamines
Drug Biological model Mechanisms Dose/time of exposure Reference
Meth, MDMA In vivo: rat brain, cortex Active caspase-3 40 mg/kg Warren et al. (2007)
Active calpain-1 Meth: 48 h
MDMA: 24 h
MDMA PC12 cells Chromatin condensation 3 mM, 24 h Milhazes et al. (2006)
MDMA Rat cortical neurons Stimulation of 5HT2A receptor 200–1600 μM Capela et al. (2006b)
Meth In vivo: mouse striatum TUNEL-positive cells 30 mg/kg, i.p. Zhu et al. (2006)
Tested 24 h later
D-Amph Rat cortical neurons Caspases -2, -9 and -3 Acute (24 h) 500 μM Cunha-Oliveira et al.
(2006a)↓ΔΨm
Apoptotic nuclear morphology
Meth In vivo: rat striatum Multiple injection — ↑Bax Multiple injection (4×5 mg/kg, i.p.) Pereira et al. (2006b)
No caspase-3 activation Single injection (1×20 mg/kg, i.p.)
D-Amph In vivo: mouse medium
spiny striatal neurons
Mitochondrial apoptotic pathway Repeated: 10 mg/kg, 4 times, every
2 h
Krasnova et al. (2005)
Caspase-3, ↑p53, ↑Bax, ↓Bcl-2
Bax-KO mice are resistant
Meth, MDMA Rat cerebellar granule
cells
Caspase-3; ROS, cytochrome c Acute (48 h, 1–5 mM) Jimenez et al. (2004)
D-Amph PC12 cells Caspase-3 Acute (5 h, 300 μM) Oliveira et al. (2003)
Cytochrome c
D-Amph PC12 cells ↓ATP/ADP Acute (96 h, 1 mM) Oliveira et al. (2002)
Apoptotic nuclear morphology
Meth In vivo: mouse striatum ↑p53; ↓Bcl-2 Repeated: 10 mg/kg, 4 times, every
2 h
Imam et al. (2001)
D-Amph, Meth,
MDMA
Neocortical neurons Bcl-xL/s changes, c-Jun Acute (1–96 h, 125 μM–1 mM) Stumm et al. (1999)
Apoptosis evaluated at 96 h, 500 μM
Meth Immortalized neural cells
from rat mesencephalon
Apoptosis 1–3 mM (24 h) Cadet et al. (1997)
Protection by Bcl-2 overexpression
ROS?
Abbreviations: Meth — methamphetamine, D-Amph — D-amphetamine, MDMA — ecstasy, MDA —malondialdehyde.
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sure has been reported in the rat frontal cortex (Warren et al.,
2007) and medium spiny striatal neurons (Krasnova et al.,
2005) of exposed animals, as well as in rat cortical neurons
(Cunha-Oliveira et al., 2006a), rat cerebellar granule cells
(Jimenez et al., 2004) and PC12 cells (Oliveira et al., 2003).
Caspase activation mediated by D-amphetamine or metham-
phetamine has been suggested to be mediated by the
mitochondrial apoptotic pathway, as indicated by the obser-
vation of cytochrome c release (Oliveira et al., 2003; Jimenez
et al., 2004), accompanied by a decrease in mitochondrial
potential (Cunha-Oliveira et al., 2006a), and a decrease in Bcl-
2/Bax levels (Krasnova et al., 2005; Imam et al., 2001). More-
over, Bcl-2 overexpression was shown to protect mesence-
phalic immortalized cells from methamphetamine-induced
apoptosis (Cadet et al., 1997). Some studies also implicated p53
in the apoptotic process induced by D-amphetamine (Kras-
nova et al., 2005) and methamphetamine (Imam et al., 2001).
Morphological features of apoptosis induced by D-ampheta-
mine were observed upon in vitro (Oliveira et al., 2002; Cunha-
Oliveira et al., 2006a) and in vivo (Dietrich et al., 2005) exposure.
Furthermore, TUNEL-positive cells were observed in the
striatum of methamphetamine exposed mice (Zhu et al.,
2006).
MDMA also induces apoptotic features in PC12 cells
(Milhazes et al., 2006) and in rat cortical neurons (Capela
et al., 2006b). MDMA-induced apoptosis in rat cortical neurons
seems to be dependent on 5-HT2A receptor activation (Capela
et al., 2006b).2.4.2.2. Cocaine and apoptosis. Cocaine neurotoxicity has
been associated with the induction of biochemical features of
apoptosis, suchasactivationof caspases (Deyet al., 2007; Cunha-
Oliveira et al., 2006a; Imam et al., 2005; Oliveira et al., 2003;
Mitchell andSnyder-Keller, 2003), lossofmitochondrial potential
and cytochrome c release (Oliveira et al., 2003; Cunha-Oliveira
et al., 2006a). However,morphological features of apoptosiswere
not evident upon in vivo (Dietrich et al., 2005) or in vitro (Oliveira
et al., 2002; Cunha-Oliveira et al., 2006a) exposure to cocaine,
except in one study from Nassogne et al. (1997). Cell death
induced by cocaine in human neuronal progenitor cells, invol-
ving cytochrome c release, seems to be preceded by oxidative
stress (Poon et al., 2007). Recent studies showing evidences of
apoptosis induced by cocaine are summarized in Table 6.
2.4.2.3. Opiates and apoptosis. Although there are some
studies reporting heroin (Fecho and Lysle, 2000) andmorphine
(Bhat et al., 2004) cytotoxicity, the molecular mechanisms of
neurotoxicity induced by these opiate drugs is scarcely
documented. However, a few studies have shown the involve-
ment of apoptosis in neuronal dysfunction induced by opiates
in mouse cortex and hippocampus (Tramullas et al., 2008), rat
spinal cord (Mao et al., 2002; Lim et al., 2005), in fetal human
neurons (Hu et al., 2002), rat cortical neurons (Cunha-Oliveira
et al., 2007) and in PC12 cells (Oliveira et al., 2002; Oliveira et al.,
2003) (Table 7). Street heroin and morphine seem to induce
apoptosis involving cytochrome c release (Oliveira et al., 2003;
Cunha-Oliveira et al., 2007), caspase activation (Lim et al.,
2005; Oliveira et al., 2003; Mao et al., 2002; Hu et al., 2002;
Table 6 – Summary of recent studies presenting evidences of neuronal apoptosis induced by cocaine
Biological model Mechanisms Dose/time of exposure Reference
Fetal locus coeruleus neurons Bax/Bcl-2 Acute (30 min–24 h) 500 ng/ml Dey et al. (2007)
Caspase-3
Human neuronal progenitor cells Oxidative stress (48 h) Acute (30 min) Poon et al. (2007)
Cell death (LDH leakage, 72 h)
Rat cortical neurons Loss of metabolic viability Acute (24 h) 1 mM Cunha-Oliveira et al. (2006a)




PC12 cells Immediate early genes Acute (24 h) 50–2500 μM Imam et al. (2005)
Transcription factors
Caspases
In vivo: rat — dopaminergic
brain structures
No apoptosis 20 mg/kg/day Dietrich et al. (2005)
Acute — 1 day
Chronic — 10 days
PC12 cells Caspase-3 Acute (5 h) 300 μM Oliveira et al. (2003)
Cytochrome c
In vivo: prenatal exposure —
rat brains
c-Fos Acute (binge 3×15 mg/kg — 1 h
interval in the day before birth
Mitchell and Snyder-Keller (2003)
Caspases Evaluated 24 h after birth
Mouse cortical cocultures DNA fragmentation 0.5 mM, 48–108 h Nassogne et al. (1997)
Cromatin condensation
↓ MAP-2 content
Abbreviations: ΔΨm — mitochondrial potential, MAP-2 — microtubule associated protein 2, LDH — lactate dehydrogenase, TUNEL — terminal
dUTP nick-end labelling.
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(Mao et al., 2002; Cunha-Oliveira et al., 2007). Recently, it was
shown that chronic heroin exposure induced the upregulation
of the pro-apoptotic proteins Fas, FasL and Bad, in the
mouse cortex and hippocampus (Tramullas et al., 2008).
Morphological hallmarks of apoptosis have also been observed
in in vitro models upon street heroin exposure (Oliveira et al.,
2002; Cunha-Oliveira et al., 2007), andwere prevented by using
a broad-range caspase inhibitor. Moreover, TUNEL-positiveTable 7 – Summary of recent studies presenting evidences of
Drug Biological model Mechanisms





Heroin Rat cortical neurons Cytochrome c release
↓ΔΨm
Caspase-2, -9 and -3 activation
↓Bcl-2/Bax
Apoptotic nuclear morphology prevent
caspase inhibitor
Morphine In vivo: rat spinal
cord
Caspase-3, MAPK, PKA
Heroin PC12 cells Cytochrome c
Caspase-3
Heroin PC12 cells ↑Dopamine metabolism
Apoptotic nuclear morphology








Abbreviations: FasL — Fas ligand, MAPK — mitogen activated protein kincells were detected scattered in the brains of mice chronic-
ally exposed to heroin (Tramullas et al., 2008). In addition,
we have recently shown that street heroin-induced apopto-
sis in rat cortical neurons also involves a significant loss
of mitochondrial membrane potential (Cunha-Oliveira
et al., 2007).
Although the extrinsic apoptotic pathway may be involved
in heroin neurotoxicity, mitochondria seem to be important
mediators of opiate-induced neurotoxic effects.neuronal apoptosis induced by opiates
Dose/time of exposure Reference
impaired 5 mg/kg (s.c.), 12 h intervals,
2 months
Tramullas et al. (2008)
128 μg/ml (215 μM heroin) 24 h Cunha-Oliveira et al.
(2007)
ed by
10 μg, twice daily, 7 days Lim et al. (2005)
30 μM (without serum) — 5 h Oliveira et al. (2003)
300 μM–4 days Oliveira et al. (2002)
20 μg, twice daily for 7 days Mao et al. (2002)
1 μM (without serum) — 5 days Hu et al. (2002)
ase, PKA — protein kinase A, NMDA — N-methyl-D-aspartate.
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heroin effects — the role of mitochondrial dysfunction.
Amphetamine and amphetamine derivatives induce apoptosis
upon acute and repeated exposures (see Table 5). Apoptotic
pathways induced by amphetamine andmethamphetamine in
neurons seem to be mainly mediated by the mitochondrial
apoptotic pathway, associated with a decrease in Bcl-2 levels
and direct interferencewith themitochondrial transmembrane
potential. Moreover, cocaine has been described to activate the
mitochondrial apoptotic pathway (see Table 6). Cocaine seems
to be less toxic than amphetamine, and in most studies
apoptotic neuronswere not observed upon exposure to cocaine
(Dietrich et al., 2005; Cunha-Oliveira et al., 2006a; Oliveira et al.,
2002). The differential effects of cocaine and amphetaminemay
be explained by the fact that these drugs have distinct effects in
themitochondria, as assessed by using NT-2 rho zero (depleted
of mitochondrial DNA) versus NT-2 rho plus cells (Cunha-
Oliveira et al., 2006a). Cocaine toxicity was less evident in NT-2
rho zero cells, compared to NT-2 rho plus cells, indicating that
the mitochondrial respiratory chain is partially involved in
cocaine toxicity in NT-2 rho plus cells. In contrast, ampheta-
mine toxicity was potentiated in NT-2 rho zero cells. Consider-
ing that NT-2 rho zero cells do not have a functional
mitochondrial respiratory chain and that amphetamine
induced a significant loss of mitochondrial potential in cortical
neurons (Cunha-Oliveira et al., 2006a), the effect of ampheta-
mine in NT-2 rho zero cells can be explained by the inability of
rho zero cells to cope with stimuli that largely affected the
mitochondrial potential. Also, in contrastwith cocaine, amphe-
tamine caused a decrease in intracellular ATP/ADP (Oliveira
et al., 2002). Street heroin exposure also appears to affect the
mitochondria in neurons, by inducing a significant loss of
mitochondrial potential, which was associated with the activa-
tion of the mitochondrial apoptotic pathway. However, the
effects of street heroin might not be solely attributed to heroinFig. 2 – Molecular and cellular mechanisms involved in the neur
neuropathology of addiction.itself, since heroin hydrochloride did not exhibit the same
apoptotic effects (Cunha-Oliveira et al., 2007), but implicate that
the cocktail of compounds consumed by heroin addicts may
increase the neurotoxic risk to which they are exposed.
Many studies reported in this review showbiochemical and
morphological evidences of cell death induced by drugs of
abuse using in vitro models. Indeed, in vivo studies may
underestimate cell death occurring upon exposure to the
drugs of abuse, because phagocytes remove apoptotic cells (Li
et al., 2003). Moreover, in vivo, different cells in a tissue are not
exposed to the toxic agents at the same time, as it occurs in
vitro. In vivo, cell death certainly initiates and progresses at
different time points, and thus may be difficult to detect. In
addition, in vivo, brain cells are organized in circuits and the
presence of more than one cell type and the interactions that
occur between cellsmayalter cell susceptibility. These reasons
may affect the analysis of dying cells in a tissue. Therefore, the
study of cell death induced by the drugs of abuse using in vitro
systems may help to determine the susceptibility of different
cell types in the nervous system and may thus be useful to
identify molecular targets for neuroprotective strategies.3. Inhibition of neurogenesis
Besides being toxic to neurons, drugs of abuse have been also
shown to induce a decrease in hippocampal neurogenesis
(reviewed by Eisch and Harburg, 2006), compromising the
capacity of the brain to generate new neurons.
In the adultmammalian brain there are twomainneurogenic
regions, the subventricular zone (SVZ) and the subgranular zone
(SGZ) of the dentate gyrus in the hippocampus (reviewed by
Gage, 2002).
Morphineandheroin induceadecrease inSGZneurogenesis
(Eisch et al., 2000). Cocaine (Yamaguchi et al., 2004; Mackowiakotoxicity of drugs of abuse, which may explain the
204 B R A I N R E S E A R C H R E V I E W S 5 8 ( 2 0 0 8 ) 1 9 2 – 2 0 8et al., 2005) and methamphetamine (Teuchert-Noodt et al.,
2000) were also reported to decrease hippocampal neurogen-
esis. Repeated or chronic exposure seems to be required to
observe the inhibition in adult hippocampal neurogenesis
induced by opiates or psychostimulants (Eisch and Harburg,
2006).
Although the mechanisms involved in the decrease in
neurogenesis induced by drugs of abuse are just starting to be
investigated, they may be related with alteration of the
proliferative environment, direct action of the drugs of abuse
in the progenitor cells and/or alteration of the cell cycle of SGZ
(Eisch and Harburg, 2006).
The effect of drugs of abuse on neurogenesis seems to be
selective for the SGZ, and does not seem to occur in the SVZ
(Nixon and Crews, 2004). A decrease in hippocampal neuro-
genesismay result in long-lasting effects on learning, memory
and cognition.4. Conclusions
Addictions are the most expensive neuropsychiatric disor-
ders, with both medical and social consequences. In the last
decades, much progress has been achieved in the clarification
of the molecular and cellular mechanisms of action of the
drugs of abuse in the brain, and drug addiction is now
considered a brain disease, as the abuse of drugs was shown
to have both acute and chronic neurotoxic consequences. The
mechanisms involved in the neurotoxicity of these drugs
include oxidative stress, apoptosis,mitochondrial dysfunction
and inhibition of neurogenesis (Fig. 2).
Despite this progress, efficient treatments that prevent
relapse have not been developed (Kreek et al., 2002; Volkow
and Li, 2005). Relapse is probably mediated by the long-lasting
changes in brain function induced by the drugs of abuse. Thus,
interference with the long-termmolecular and cellular effects
of the drugs of abuse may constitute important pharmacolo-
gical targets to prevent relapse.
Thus, understanding the mechanisms that underlie the
brain dysfunction observed in drug-addicted individuals may
contribute to improve the treatment of drug addiction.
Molecular and cellular studies suggest that other therapeutic
targets may be explored in the future, such as the prevention
drug-induced neuronal dysfunction and neurotoxicity.Acknowledgments
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